Global Women's Health Pharma Report 2018
Global Women's Health Pharma Report 2018
DUBLIN, March 15, 2018 /PRNewswire/ --
The "Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline" drug pipelines has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report assesses first-in-class innovation across the women's health therapy area, with a particular focus on three key indications: endometriosis, polycystic ovarian syndrome (PCOS) and cervical intraepithelial neoplasia (CIN).
The women's health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.
Despite this, the women's health market is relatively small. This reflects diagnostic barriers and high levels of non-treatment for women's health disorders, as well as high levels of genericization and relatively limited innovation within recent decades.
Consequently, there is strong rationale for continued R&D investment in women's health therapeutics due to high levels of unmet need across many indications.
Scope
-- Many women's health disorders are highly prevalent. How do epidemiology
trends vary for endometriosis, PCOS and CIN?
-- Innovation within women's health has been relatively limited over recent
decades. What are the most prominent unmet needs across this therapy
area?
-- There are 261 pipeline programs in active development for women's
health. What proportion of these products are first-in-class? How does
first-in-class innovation vary by indication, development stage and
molecular target class?
-- Although the first-in-class pipeline is relatively modest in size it is
considerably diverse with eight distinct molecular target classes
represented. Which first-in-class targets have been identified as most
promising for women's health conditions?
-- Over 200 licensing deals relating to women's health have been completed
since 2006. Do women's health products typically attract high deal
values? Which first-in-class products have prior deal involvement?
Key Topics Covered:
1 Table of Contents
2 Executive Summary
-- Expanding Pipeline Has Potential to Address Unmet Needs of Large
Prevalence Population
-- First-in-Class Innovation Concentrated Across Endometriosis, Polycystic
Ovarian Syndrome and Cervical Intraepithelial Neoplasia
-- Despite High Licensing Deal Activity, Most First-in-Class Products Have
No Prior Deal Involvement
3 The Case for Innovation
-- Growing Opportunities for Biologic Products
-- Diversification of Molecular Targets
-- Innovative First-in-Class Product Developments Remain Attractive
-- Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product
Innovation
-- Sustained Innovation in Women's Health
-- Research Report Guidance
4 Clinical and Commercial Landscape
-- Therapy Area Overview
-- Disease Overview and Symptoms
-- Diagnosis
-- Epidemiology and Etiology
-- Pathophysiology
-- Co-morbidities and Complications
-- Treatment
-- Overview of Marketed Products within Women's Health
5 Pipeline Assessment
-- Overview
-- Pipeline by Stage of Development and Molecule Type
-- Pipeline by Molecular Target
-- Comparative Distribution of Programs between the Market and Pipeline by
Molecular Target Class
-- First-in-Class Programs Targeting Novel Molecular Targets
-- Ratio of First-in-Class Products to First-in-Class Targets
-- List of All Pipeline Products
6 Signalling Network, Disease Causation and Innovation Alignment
-- Complexity of Signaling Networks
-- Signaling Pathways and First-in-Class Molecular Target Integration
-- First-in-Class Matrix Assessments
7 First-in-Class Target Evaluation
-- First-in-Class Programs Targeting Prostaglandin E2 Receptor EP4 Subtype
(PTGER4) for Endometriosis
-- First-in-Class Programs Targeting Patatin-Like Phospholipase Domain
Containing Protein 2 (PNPLA2) for Endometriosis, PCOS and Ovarian
Hyperstimulation Syndrome
-- First-in-Class Programs Targeting Glutamyl Aminopeptidase (ENPEP) for
Endometriosis
-- First-in-Class Programs Targeting Prostaglandin E Synthase (PTGES) for
Endometriosis
-- First-in-Class Programs Targeting Kiss 1 Receptor (KISS1R) for
Endometriosis, PCOS and Infertility
-- First-in-Class Programs Targeting Interleukin-1 Receptor Associated
Kinase 4 (IRAK4) for Endometriosis
-- First-in-Class Programs Targeting Type 2 Angiotensin II Receptor (AGTR2)
for PCOS
-- First-in-Class Programs Targeting Neuromedin K Receptor (TACR3) for
PCOS, Endometriosis, Uterine Fibroids and Vasomotor Symptoms of
Menopause
-- First-in-Class Programs Targeting Eukaryotic Translation Initiation
Factor 2 Alpha Kinase 3 (EIF2AK3) for CIN
-- First-in-Class Programs Targeting Human Papillomavirus Protein E6 (E6)
and Human Papillomavirus Protein E7 for CIN
8 Strategic Consolidations
-- First-in-Class Products with and without Prior Deal Involvement in
Licensing and Co-development Deals
-- Industry-Wide First-in-Class Deals
-- Licensing Deals
-- Co-Development Deals
-- First-in-Class Programs with and without Prior Deal Involvement
9 Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zt6rbp/global_womens?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-womens-health-pharma-report-2018-300614734.html
SOURCE Research and Markets
